Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

224 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Continued benefit of nusinersen initiated in the presymptomatic stage of spinal muscular atrophy: 5-year update of the NURTURE study.
Crawford TO, Swoboda KJ, De Vivo DC, Bertini E, Hwu WL, Finkel RS, Kirschner J, Kuntz NL, Nazario AN, Parsons JA, Pechmann A, Ryan MM, Butterfield RJ, Topaloglu H, Ben-Omran T, Sansone VA, Jong YJ, Shu F, Zhu C, Raynaud S, Lago TR, Paradis AD, Foster R, Chin R, Berger Z; NURTURE Study Group. Crawford TO, et al. Among authors: berger z. Muscle Nerve. 2023 Aug;68(2):157-170. doi: 10.1002/mus.27853. Epub 2023 Jul 6. Muscle Nerve. 2023. PMID: 37409780
Restoration of Nusinersen Levels Following Treatment Interruption in People With Spinal Muscular Atrophy: Simulations Based on a Population Pharmacokinetic Model.
MacCannell D, Berger Z, Kirschner J, Mercuri E, Farrar MA, Iannaccone ST, Kuntz NL, Finkel RS, Valente M, Muntoni F. MacCannell D, et al. Among authors: berger z. CNS Drugs. 2022 Feb;36(2):181-190. doi: 10.1007/s40263-022-00899-0. Epub 2022 Jan 26. CNS Drugs. 2022. PMID: 35080757 Free PMC article.
Scientific rationale for a higher dose of nusinersen.
Finkel RS, Ryan MM, Pascual Pascual SI, Day JW, Mercuri E, De Vivo DC, Foster R, Montes J, Gurgel-Giannetti J, MacCannell D, Berger Z. Finkel RS, et al. Among authors: berger z. Ann Clin Transl Neurol. 2022 Jun;9(6):819-829. doi: 10.1002/acn3.51562. Epub 2022 May 13. Ann Clin Transl Neurol. 2022. PMID: 35567345 Free PMC article.
Corrigendum to 'Population pharmacokinetics-based recommendations for a single delayed or missed dose of nusinersen': Neuromuscular Disorders 31 (2021) 310-318/doi: 10.1016/j.nmd.2021.02.014.
MacCannell D, Berger Z, East L, Mercuri E, Kirschner J, Muntoni F, Farrar MA, Peng J, Zhou J, Nestorov I, Farwell W, Finkel RS. MacCannell D, et al. Among authors: berger z. Neuromuscul Disord. 2022 Jan;32(1):e1. doi: 10.1016/j.nmd.2022.01.002. Neuromuscul Disord. 2022. PMID: 35144755 Free article. No abstract available.
A pediatric quantitative systems pharmacology model of neurofilament trafficking in spinal muscular atrophy treated with the antisense oligonucleotide nusinersen.
Paris A, Bora P, Parolo S, MacCannell D, Monine M, van der Munnik N, Tong X, Eraly S, Berger Z, Graham D, Ferguson T, Domenici E, Nestorov I, Marchetti L. Paris A, et al. Among authors: berger z. CPT Pharmacometrics Syst Pharmacol. 2023 Feb;12(2):196-206. doi: 10.1002/psp4.12890. Epub 2022 Dec 5. CPT Pharmacometrics Syst Pharmacol. 2023. PMID: 36471456 Free PMC article.
End-of-life care for the devout Jewish patient.
Eitingon J, Doberman D, Berger Z, Tapper CX. Eitingon J, et al. Among authors: berger z. J Eval Clin Pract. 2024 Aug 6. doi: 10.1111/jep.14109. Online ahead of print. J Eval Clin Pract. 2024. PMID: 39108047
224 results